Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Predicting Chemotherapy Resistance in AML.

Cecilia C S Yeung1, Jerald Radich2

  • 1Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, G7-910, Seattle, WA, 98109, USA. cyeung@fredhutch.org.

Current Hematologic Malignancy Reports
|April 12, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Graphical and interactive spatial proteomics image analysis workflow.

GigaByte (Hong Kong, China)·2026
Same author

Introduction to the Review Series. Chronic myeloid leukemia in 2026.

Haematologica·2026
Same author

The first-in-human ENCIT01 trial comparing second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Chronic Myeloid Leukemia in Low- and Middle-Income Countries. Reply.

The New England journal of medicine·2026
Same author

Portrait of a Pioneer: Fred Appelbaum.

Transplantation and cellular therapy·2026
Same author

Development, characterization, and inter-laboratory validation of methylated human cell free DNA candidate reference materials.

Clinical epigenetics·2026

Chemotherapy resistance in acute myeloid leukemia (AML) remains a significant challenge, with new resistance mechanisms emerging even with targeted therapies. This review explores primary, de novo, and acquired resistance in AML.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute myeloid leukemia (AML) is the most prevalent acute leukemia, featuring diverse cytogenetic and molecular subtypes affecting patient outcomes.
  • Despite extensive research and numerous clinical trials, treatment responses and survival rates in AML have remained largely unchanged.
  • Chemotherapy resistance is a critical unresolved issue in AML management.

Purpose of the Study:

  • To review established and emerging mechanisms of chemotherapy resistance in acute myeloid leukemia.
  • To discuss primary treatment resistance, de novo resistance, and acquired resistance.
  • To explore resistance mechanisms related to leukemic blasts and host factors.

Main Methods:

  • Comprehensive literature review of studies on acute myeloid leukemia treatment resistance.
Keywords:
Acute myeloid leukemiaChemotherapy resistanceMinimal residual diseaseMolecular diagnosticsTumor heterogeneity

Related Experiment Videos

  • Analysis of primary, de novo, and acquired resistance mechanisms.
  • Examination of resistance linked to leukemic cell biology and host-related factors.

    • Main Results:

    • Chemotherapy resistance is a complex, multifactorial problem in AML.
    • Novel targeted therapies have revealed new pathways contributing to treatment resistance.
    • Resistance mechanisms involve intrinsic leukemic cell properties and external host factors.

    Conclusions:

    • Understanding the diverse mechanisms of AML chemotherapy resistance is crucial for improving treatment efficacy.
    • Addressing both primary and acquired resistance is essential for overcoming treatment failures.
    • Further research into resistance pathways may lead to more effective therapeutic strategies for AML patients.